ArticleNeurochemical research2026
Olfactory Mucosa MSCs-Derived Exosomal RPL6 Attenuates Seizure-Induced Neuronal Damage via FGF2-Mediated Oxidative Stress and Mitophagy.
Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unraveling the role of FGF21 in epilepsy disease: mechanistic insights and therapeutic Potential.Metabolic brain disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Evidence suggests that olfactory mucosa-derived mesenchymal stem cells (OM-MSCs) can benefit epilepsy treatment in both clinical patients and mouse models, although their precise mechanism remains unclear. Given the advantages of exosomes in precise cellular regulation, ease of storage, and long-term stability, this study investigated the role of OM-MSCs-derived exosomes (OM-MSCs-exos) in status epilepticus (SE) models. Here, SE mouse models were induced by intraperitoneal injection of pilocarpine. OM-MSCs, differentially treated OM-MSCs-exos, and recombinant FGF2 protein were injected into SE model mice to investigate the effects of OM-MSCs-exos on SE models and their potential mechanisms. Functionally, treatment with OM-MSCs and OM-MSCs-exos significantly improved cognitive function, as evidenced by increased target quadrant duration, decreased escape latency, increased average speed, and more platform crossings in behavioral tests. Furthermore, this treatment further alleviated hippocampal tissue damage by reversing pilocarpine-induced oxidative damage, neuronal injury, and excessive mitophagy. Consistent outcomes were confirmed in vitro. Mechanistically, RPL6 was screened and confirmed as a key protein in OM-MSCs-exos, which interacts with FGF2 to promote FGF2 expression, thereby alleviating oxidative stress and mitochondrial dysfunction induced by H
Indexed as
Identifiers
42277443What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.